Literature DB >> 33398482

Oil-Immersion Flow Imaging Microscopy for Quantification and Morphological Characterization of Submicron Particles in Biopharmaceuticals.

Nils Krause1, Sebastian Kuhn2, Erik Frotscher2, Felix Nikels2, Andrea Hawe1, Patrick Garidel2, Tim Menzen3.   

Abstract

Flow imaging microscopy (FIM) is widely used to analyze subvisible particles starting from 2 μm in biopharmaceuticals. Recently, an oil-immersion FIM system emerged, the FlowCam Nano, designed to enable the characterization of particle sizes even below 2 μm. The aim of our study was to evaluate oil-immersion FIM (by using FlowCam Nano) in comparison to microfluidic resistive pulse sensing and resonant mass measurement for sizing and counting of particles in the submicron range. Polystyrene beads, a heat-stressed monoclonal antibody formulation and a silicone oil emulsion, were measured to assess the performance on biopharmaceutical relevant samples, as well as the ability to distinguish particle types based on instrument-derived morphological parameters. The determination of particle sizes and morphologies suffers from inaccuracies due to a low image contrast of small particles and light-scattering effects. The ill-defined measured volume impairs an accurate concentration determination. Nevertheless, FlowCam Nano in its current design complements the limited toolbox of submicron particle analysis of biopharmaceuticals by providing particle images in a size range that was previously not accessible with commercial FIM instruments.

Entities:  

Keywords:  FlowCam Nano; microfluidic resistive pulse sensing; particle detection; protein particle analytics; silicone oil droplets

Year:  2021        PMID: 33398482     DOI: 10.1208/s12248-020-00547-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  28 in total

Review 1.  Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation.

Authors:  Eva Y Chi; Sampathkumar Krishnan; Theodore W Randolph; John F Carpenter
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

2.  Classification of protein aggregates.

Authors:  Linda O Narhi; Jeremy Schmit; Karoline Bechtold-Peters; Deepak Sharma
Journal:  J Pharm Sci       Date:  2011-10-11       Impact factor: 3.534

3.  Factors Governing the Precision of Subvisible Particle Measurement Methods - A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe.

Authors:  Anacelia Ríos Quiroz; Jens Lamerz; Thierry Da Cunha; Adeline Boillon; Michael Adler; Christof Finkler; Joerg Huwyler; Roland Schmidt; Hanns-Christian Mahler; Atanas V Koulov
Journal:  Pharm Res       Date:  2015-10-16       Impact factor: 4.200

Review 4.  Immunogenicity of Therapeutic Protein Aggregates.

Authors:  Ehab M Moussa; Jainik P Panchal; Balakrishnan S Moorthy; Janice S Blum; Marisa K Joubert; Linda O Narhi; Elizabeth M Topp
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

Review 5.  Protein aggregation: pathways, induction factors and analysis.

Authors:  Hanns-Christian Mahler; Wolfgang Friess; Ulla Grauschopf; Sylvia Kiese
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

Review 6.  Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.

Authors:  Linda O Narhi; Vincent Corvari; Dean C Ripple; Nataliya Afonina; Irene Cecchini; Michael R Defelippis; Patrick Garidel; Andrea Herre; Atanas V Koulov; Tony Lubiniecki; Hanns-Christian Mahler; Paolo Mangiagalli; Douglas Nesta; Bernardo Perez-Ramirez; Alla Polozova; Mara Rossi; Roland Schmidt; Robert Simler; Satish Singh; Thomas M Spitznagel; Andrew Weiskopf; Klaus Wuchner
Journal:  J Pharm Sci       Date:  2015-04-01       Impact factor: 3.534

7.  A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.

Authors:  Mario Hubert; Dennis T Yang; Stanley C Kwok; Anacelia Rios; Tapan K Das; Ankit Patel; Klaus Wuchner; Valentyn Antochshuk; Friederike Junge; George M Bou-Assaf; Shawn Cao; Miguel Saggu; Luis Montrond; Nataliya Afonina; Parag Kolhe; Vakhtang Loladze; Linda Narhi
Journal:  J Pharm Sci       Date:  2019-10-21       Impact factor: 3.534

8.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.

Authors:  John F Carpenter; Theodore W Randolph; Wim Jiskoot; Daan J A Crommelin; C Russell Middaugh; Gerhard Winter; Ying-Xin Fan; Susan Kirshner; Daniela Verthelyi; Steven Kozlowski; Kathleen A Clouse; Patrick G Swann; Amy Rosenberg; Barry Cherney
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

Review 9.  Protein aggregation and its impact on product quality.

Authors:  Christopher J Roberts
Journal:  Curr Opin Biotechnol       Date:  2014-08-28       Impact factor: 9.740

10.  Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in Mice.

Authors:  Grzegorz Kijanka; Jared S Bee; Samuel A Korman; Yuling Wu; Lorin K Roskos; Mark A Schenerman; Bram Slütter; Wim Jiskoot
Journal:  J Pharm Sci       Date:  2018-07-10       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.